Drug companion protocol
Mazdutide
A dual GLP-1 / glucagon receptor agonist under clinical development for weight management and metabolic disease.
Quickstart Highlights
- Drug class
- GLP-1 / glucagon dual receptor agonist
- Route
- Subcutaneous injection
- Schedule
- Weekly subcutaneous injection
- Evidence score
- 42
Quickstart highlights
- ๐Subcutaneous injection
- ๐ฌGLP-1 / glucagon dual receptor agonist
- ๐Prescription required
How this works
Mechanism of action and pharmacokinetic profile from published data.
Mazdutide (also known as IBI362 or OXM3) is a dual GLP-1 / glucagon receptor agonist. Like retatrutide, it activates the glucagon receptor โ which promotes energy expenditure, fat oxidation, and liver-fat reduction โ alongside the GLP-1 receptor for appetite suppression and insulin regulation. Mazdutide is in clinical development primarily in China (Innovent Biologics), with Phase 3 trials underway in China and Phase 2 data published in the Lancet Diabetes & Endocrinology for type 2 diabetes.
- Time to peak (Tmax)
- ~48โ72 hours after subcutaneous injection.
- Clearance
- Proteolytic degradation; full clearance characterisation is ongoing in Phase 3.
- Elimination half-life
- Approximately 3.5โ4 days based on Phase 2 data; supports once-weekly or less-frequent dosing.
- Bioavailability
- Published from Phase 2 investigational data in Chinese populations; not yet on a product label for other regions.
Clinical Benefits & Side Effects
Observed outcomes, adverse effects, and lifecycle considerations from published trial data.
Benefits
Investigational status
Mazdutide is approved in China and in Phase 3 trials there; it remains investigational elsewhere. Dosing, escalation, and monitoring are trial-protocol-specific.
First injection โ taking the first step
You've taken a big step by starting your first injection. This week is all about getting familiar with the process and listening to your body. You may not notice much change yet โ that's completely normal at this early, low starting dose.
Body begins adjusting to the medication
Some people start to notice mild nausea, especially after eating or in the hours following their injection. You might also feel a little more full than usual at mealtimes. These early signals are signs your body is responding โ go gently with yourself.
Navigating nausea and early side effects
Nausea, tiredness, or loose stools are commonly reported around this time and can feel discouraging. Most people find these symptoms are manageable and begin to ease with small, simple meals. Hang in there โ this phase is temporary for most people.
Completing your first month โ finding your rhythm
You've made it through your first month โ that's worth acknowledging! Side effects may still be present but often start to settle. The scale may not have shifted much yet, and that's okay; your body is still adjusting to the medication.
Dose may increase โ appetite changes ahead
Depending on your prescriber's plan, your dose may be increased around this point. With a higher dose, you might notice a more noticeable reduction in appetite or earlier feelings of fullness at meals. Follow your prescriber's instructions closely during this escalation phase.
Appetite suppression becoming more noticeable
Many people report that food simply doesn't feel as appealing this week, or that they feel satisfied with much smaller portions. It's important to still eat regular, balanced meals โ your body needs consistent fuel even when hunger signals are quieter.
Energy and mood may start to stabilise
As your body adapts to the higher dose, energy levels often begin to even out. Some people experience a second wave of nausea with dose escalation โ eating slowly, avoiding rich foods, and staying well hydrated can help manage this.
Side effects
Common; most frequent at 6 mg
Reported
Reported
Common; generally expected
Reported; generally mild
Lifecycle factors
Mazdutide is investigational outside China
Phase 3 trials are underway in China and some early Phase 2 data are international; the drug does not have TGA, FDA, MHRA, or EMA approval. Any questions about access or participation should go to your trial site.
Glucagon co-activation distinguishes this class
The glucagon receptor component of dual GLP-1/glucagon agonists like mazdutide and retatrutide is thought to increase energy expenditure โ a mechanism not present in pure GLP-1 agonists. Phase 2 data suggest this may be particularly effective for liver-fat reduction (NASH/MAFLD).
Store your medication correctly in the Australian climate
Australian summers can get extremely hot, and heat can degrade injectable medications quickly. Always store your pen in the fridge (typically **2โ8ยฐC**) and never leave it in a hot car, direct sunlight, or a warm bathroom cabinet. If you're travelling, use a medical-grade insulated travel pouch designed for injectable pens โ these are available at most Australian pharmacies.
Important note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All information presented is based on published clinical trial data. Always follow your prescriber's instructions.
Nutrition & practical guidance
Food, hydration, and adherence tips compiled from trial data and clinical companion content.
Food and hydration
โ Prefer
โ ๏ธ Limit
Adherence tips
Rotate your injection sites consistently
Always rotate between recommended injection areas โ typically the abdomen (at least 5 cm from your belly button), front of the thigh, or upper arm. Rotating sites within each area each week helps prevent lumps or skin irritation building up at one spot. Keep a simple note on your phone or a sticky note on your pen to track where you last injected.
Let your pen reach room temperature before injecting
Injecting medication that's straight from the fridge can sting more and feel uncomfortable. Take your pen out of the fridge **15โ30 minutes before** your scheduled injection and let it warm to room temperature. Never use a microwave or warm water to heat it โ just leave it on the bench. Follow your prescriber's instructions for storage between uses.
Pick an injection day you can stick to every week
Choose a day of the week that works for your schedule โ such as Sunday morning before breakfast or Wednesday evening โ and stick to it. Consistency in timing supports steady medication levels in your body. Set a recurring weekly reminder on your phone so it becomes as automatic as charging your phone.
Consider injecting on a day before a lighter schedule
Some people feel slightly fatigued or nauseous in the 12โ24 hours after their injection, especially in the early weeks. If possible, schedule your injection on a day before a lighter day โ for example, Friday evening if you have a quieter Saturday. This gives your body time to adjust without impacting a busy work day.
Liver-fat reduction context
If you are in a mazdutide trial partly because of non-alcoholic fatty liver disease, your trial team may monitor liver enzymes and imaging. A low-fat, low-fructose dietary pattern is broadly recommended alongside pharmacotherapy for liver-fat reduction.
Start every morning with a full glass of water
Before coffee, before breakfast โ drink a full 250โ300 mL glass of water as the very first thing you do each morning. This simple habit kick-starts your hydration for the day and can help reduce that early-morning nausea some people experience. Keep a glass or water bottle on your bedside table the night before as a visual cue.
Sip water steadily โ don't gulp large amounts at once
Drinking large quantities of water quickly can actually worsen nausea and feelings of bloating when your stomach is already sensitive. Instead, aim to **sip steadily throughout the day** โ a few mouthfuls every 15โ20 minutes. A 750 mL drink bottle is a practical tool for keeping track without counting glasses.
Prioritise protein at every meal, even small ones
When your appetite is reduced, it's easy to eat very little overall โ but insufficient protein can lead to muscle loss over time. Aim to include a palm-sized serve of protein at each meal: eggs at breakfast, canned tuna or legumes at lunch, and chicken or tofu at dinner. Even small amounts of protein at each sitting add up and matter.
Eat smaller meals more frequently to manage nausea
Rather than three large meals, try shifting to **4โ5 smaller eating occasions** across the day, especially in the first eight weeks. An empty stomach can sometimes make nausea worse, while overfilling it definitely will. Think of it as keeping the tank topped up rather than filling it to the brim.
Track non-scale victories alongside your weight
The number on the scale is only one small measure of progress โ and it can be frustratingly slow in the early weeks. Keep a short weekly note (even in your phone's notes app) of other changes: energy levels, how your clothes feel, how far you walked, how you slept. These 'non-scale victories' often tell a much richer story of what's actually changing in your body.
Be patient with the early weeks โ they're the hardest
The first four weeks are widely regarded as the most challenging part of starting a GLP-1-based medication. Side effects are at their most noticeable, results are least visible, and it can feel discouraging. Knowing this in advance can help you push through. Many people who persisted past week four report that things became significantly more manageable.
Start movement gently โ a 20-minute walk counts
You don't need to join a gym or start an intense program. In the early weeks, a 20-minute walk at a comfortable pace โ around the block or along a local path โ is genuinely beneficial and appropriate. As your energy and confidence grow, you can gradually increase duration or intensity. Any consistent movement is far better than none.
Add light resistance exercise to protect muscle
Because weight loss from any method can reduce muscle mass, adding some resistance-based movement โ like bodyweight squats, resistance bands, or light weights โ 2โ3 times per week is highly beneficial. It doesn't need to be intense; even a simple 15-minute home routine can make a meaningful difference. Chat with a qualified exercise professional for a plan suited to your current fitness level.
Protect your sleep โ it directly supports your results
Poor sleep increases hunger hormones and can make food cravings harder to manage โ working against the appetite changes you're trying to support with this medication. Aim for **7โ9 hours per night** and try to keep a consistent bedtime, even on weekends. If nausea is disrupting your sleep, try your injection earlier in the day and avoid eating within two hours of bed.
Communicate openly with your prescriber โ every concern counts
Your prescriber needs accurate information to support you well โ so don't hold back from telling them about side effects, how you're coping emotionally, or if something feels wrong. No concern is too minor to mention. Follow your prescriber's instructions about check-in appointments, and consider keeping a brief weekly log of symptoms to share at each visit.
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Who should not take this
Mazdutide is investigational outside China; access is limited to clinical trial participants. Based on published trial exclusion criteria and the GLP-1/glucagon class: โข Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 โข History of pancreatitis or unexplained persistent abdominal pain โข Severe GI disease โข Recent major cardiovascular events โข Pregnancy or breastfeeding โข Severe kidney or liver impairment No regulatory label exists outside trial contexts. Direct questions to your trial site.
Known interactions
- Insulin and sulfonylureassignificant
GLP-1 agonism increases insulin secretion โ combining with other insulin-stimulating agents raises hypoglycaemia risk.
- Oral contraceptivesmoderate
GLP-1-mediated gastric slowing may affect oral contraceptive absorption.
- Alcoholmoderate
Worsens nausea and GI effects; increases hypoglycaemia risk with co-administered glucose-lowering drugs.
Storage and handling
As an investigational biologic, storage is governed by the trial protocol or supplying pharmacy. GLP-1 family injectables in this class require refrigeration at 2โ8ยฐC and must not be frozen. Follow the instructions provided by your trial site.
Research evidence
Published studies connected to this peptide with dosage and outcomes context.
Efficacy and safety of mazdutide (IBI362) 4 mg and 6 mg in Chinese adults with type 2 diabetes and overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial
Human trial ยท 2023 ยท The Lancet Diabetes & Endocrinology ยท n=265 ยท Chinese adults with type 2 diabetes and BMI โฅ25, on stable metformin
265 adults were randomised to mazdutide 4 mg weekly, 6 mg weekly, or placebo for 24 weeks. HbA1c reductions were โ1.46% and โ1.81% for 4 and 6 mg respectively versus โ0.22% for placebo. Body-weight reductions were โ6.67% and โ9.73% respectively. GI adverse events were the most common, generally mild-to-moderate.
Reported outcomes
- weight_loss: Body-weight reductions of โ6.67% at 4 mg and โ9.73% at 6 mg weekly versus +0.05% for placebo. (Secondary)
- hba1c_reduction: HbA1c reductions of โ1.46% at 4 mg and โ1.81% at 6 mg weekly versus โ0.22% for placebo at 24 weeks. (Primary outcome)
Reported dosage
- 4 mg ยท once weekly subcutaneous ยท 24 weeks โ Lower dose arm in the Phase 2 T2D trial.
- 6 mg ยท once weekly subcutaneous ยท 24 weeks โ Higher dose arm; produced larger HbA1c and body-weight reductions.
Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.